[Pharmacological and clinical profile of solifenacin succinate (Vesicare) developed as a new therapeutic agent for overactive bladder]

Nihon Yakurigaku Zasshi. 2006 Dec;128(6):425-32. doi: 10.1254/fpj.128.425.
[Article in Japanese]
No abstract available

Publication types

  • Review

MeSH terms

  • Animals
  • Clinical Trials as Topic
  • Humans
  • Muscarinic Antagonists / metabolism
  • Muscarinic Antagonists / pharmacology
  • Muscarinic Antagonists / therapeutic use*
  • Muscle, Smooth / drug effects
  • Quinuclidines / metabolism
  • Quinuclidines / pharmacology
  • Quinuclidines / therapeutic use*
  • Receptors, Muscarinic / metabolism
  • Solifenacin Succinate
  • Tetrahydroisoquinolines / metabolism
  • Tetrahydroisoquinolines / pharmacology
  • Tetrahydroisoquinolines / therapeutic use*
  • Urinary Bladder / drug effects
  • Urinary Bladder, Overactive / drug therapy*
  • Urinary Bladder, Overactive / physiopathology
  • Urination / drug effects

Substances

  • Muscarinic Antagonists
  • Quinuclidines
  • Receptors, Muscarinic
  • Tetrahydroisoquinolines
  • Solifenacin Succinate